SUPERNUS PHARMACEUTICALS, INC.

Drug pipeline (8)

Asset	Stage	Revenue	Trials	Status
Amantadine Hydrochloride	approved	—	0	—
Apomorphine hydrochloride	approved	—	2	approved
BREXANOLONE	approved	—	7	approved
Oxcarbazepine	approved	—	8	approved
SAFINAMIDE MESYLATE	approved	—	0	—

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (61)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05358821	phase2	completed	2022-05-26	2024-02-29	Supernus Pharmaceuticals, Inc.	28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
NCT01114854	phase1	completed	2010-06-01	2010-12-01	Supernus Pharmaceuticals, Inc.	A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
NCT05059600	phase4	completed	2021-10-08	2022-07-14	Supernus Pharmaceuticals, Inc.	A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
NCT02477618	phase3	completed	2015-06-01	2017-07-18	Supernus Pharmaceuticals, Inc.	A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT03844906	phase1	completed	2018-12-27	2019-03-18	Supernus Pharmaceuticals, Inc.	A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

FDA applications (9)

Application

Type

Applicant

Products

NDA 021264

NDA

MDD US OPERATIONS LLC

NDA 201635

NDA

SUPERNUS PHARMACEUTICALS INC

NDA 202810

NDA

SUPERNUS PHARMACEUTICALS INC

NDA 207145

NDA

MDD US OPERATIONS LLC

NDA 208944

NDA

SUPERNUS PHARMACEUTICALS INC